Affimed (AFMD) – Press Releases
-
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
-
Affimed Reports 2023 Financial Results and Operational Progress
-
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
-
Affimed Announces 1-for-10 Reverse Stock Split
-
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
-
Affimed Announces Leadership Change and Organizational Restructuring
-
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
-
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients
-
Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (B
-
Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24
-
Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
-
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
-
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
-
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Im
-
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
-
Affimed to Participate in Upcoming Investor Conferences
-
Affimed Announces Listing Transfer to Nasdaq Capital Markets
-
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy o
-
Affimed to Present at the Cantor Global Healthcare Conference 2023
-
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
-
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
-
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
-
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
-
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
-
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
-
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
-
Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)
-
Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan
-
Affimed to Present at the 2023 Jefferies Healthcare Conference
-
Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology
-
Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress
-
Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy
-
Affimed Announces Annual General Meeting of Shareholders
-
Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023
-
Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association
-
Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)
-
Affimed Shares Preclinical Data on AFM13’s Mechanism of Action Demonstrating Its Potential to Induce Serial Killing at the American Association for Cancer Research Annual Meeting
-
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Asso
-
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
-
Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia
-
Affimed Reports 2022 Financial Results and Operational Progress
-
Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
-
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells
-
Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells
-
AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery
-
Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference
-
AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target
-
Affimed to Present at the SVB Securities 2023 Global Biopharma Conference
-
Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13
-
Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia
Back to AFMD Stock Lookup
